Comparing the efficacy in reducing brain injury of different neuroprotective agents following neonatal hypoxia–ischemia in newborn rats: a multi-drug randomized controlled screening trial

• Published in: Scientific reports Vol. 13; no. 1; p. 9467
• Main Authors: Sabir, Hemmen, Maes, Elke, Zweyer, Margit, Schleehuber, Yvonne, Imam, Farhad B., Silverman, Jared, White, Yasmine, Pang, Raymand, Pasca, Anca M., Robertson, Nicola J., Maltepe, Emin, Bernis, Maria E.
• Format: Journal Article
• Language: English
• Published: London Nature Publishing Group UK 10.06.2023; Nature Publishing Group; Nature Portfolio
• Subjects: 631/378; 631/378/1689; 631/378/1689/534; Allopurinol; Allopurinol - pharmacology; Animals; Animals, Newborn; Asphyxia Neonatorum - drug therapy; Brain; Brain Injuries - drug therapy; Brain injury; Caffeine; Caffeine - pharmacology; Clemastine - pharmacology; Disease Models, Animal; Drug development; Encephalopathy; Hedgehog Proteins; Humanities and Social Sciences; Humans; Hydroxybutyrates - pharmacology; Hypothermia; Hypothermia, Induced - methods; Hypoxia; Hypoxia - drug therapy; Hypoxia-Ischemia, Brain - drug therapy; Infant, Newborn; Iodides; Ischemia; Ischemia - therapy; Melatonin; Melatonin - pharmacology; Melatonin - therapeutic use; Morbidity; multidisciplinary; Neonates; Neuroprotection; Neuroprotective agents; Neuroprotective Agents - pharmacology; Neuroprotective Agents - therapeutic use; Rats; Science; Science (multidisciplinary); Traumatic brain injury
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-36653-9

Intrapartum hypoxia–ischemia leading to neonatal encephalopathy (NE) results in significant neonatal mortality and morbidity worldwide, with > 85% of cases occurring in low- and middle-income countries (LMIC). Therapeutic hypothermia (HT) is currently the only available safe and effective treatment of HIE in high-income countries (HIC); however, it has shown limited safety or efficacy in LMIC. Therefore, other therapies are urgently required. We aimed to compare the treatment effects of putative neuroprotective drug candidates following neonatal hypoxic-ischemic (HI) brain injury in an established P7 rat Vannucci model. We conducted the first multi-drug randomized controlled preclinical screening trial, investigating 25 potential therapeutic agents using a standardized experimental setting in which P7 rat pups were exposed to unilateral HI brain injury. The brains were analysed for unilateral hemispheric brain area loss after 7 days survival. Twenty animal experiments were performed. Eight of the 25 therapeutic agents significantly reduced brain area loss with the strongest treatment effect for Caffeine, Sonic Hedgehog Agonist (SAG) and Allopurinol, followed by Melatonin, Clemastine, ß-Hydroxybutyrate, Omegaven, and Iodide. The probability of efficacy was superior to that of HT for Caffeine, SAG, Allopurinol, Melatonin, Clemastine, ß-hydroxybutyrate, and Omegaven. We provide the results of the first systematic preclinical screening of potential neuroprotective treatments and present alternative single therapies that may be promising treatment options for HT in LMIC.